Empagliflozin for Heart Failure with Preserved Left Ventricular Ejection Fraction with and without Diabetes

Circulation.

In patients with heart failure and a preserved ejection fraction enrolled in EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction), empagliflozin significantly reduced the risk of heart failure outcomes irrespective of diabetes status at baseline.